<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>K2 Vynce - Precision Oncology</title>
    <link rel="stylesheet" href="style.css">
    <link href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700&display=swap" rel="stylesheet">
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
</head>

<body>
    <header>
        <nav class="navbar">
            <div class="logo">
                <span style="font-weight: 700; font-size: 24px; color: #202124;">K2 Vynce</span>
            </div>
            <ul class="nav-links">
                <li><a href="#problem">The Problem</a></li>
                <li><a href="#solution">The Platform</a></li>
                <li><a href="#why">Why K2 think</a></li>
                <li><a href="#demo">Demo</a></li>
            </ul>
            <div class="nav-actions">
                <a href="#" class="btn btn-secondary">Request a Demo</a>
                <a href="#" class="btn btn-primary">Sign Up</a>
            </div>
            <div class="menu-toggle">
                <i class="material-icons">menu</i>
            </div>
        </nav>
    </header>

    <main>
        <section class="hero">
            <div class="hero-content">
                <h1>A Theragnostic AI Platform for Precision NSCLC Treatment</h1>
                <p>K2 Think powers a scalable platform to identify tumor-specific molecular networks, assess inhibitor effects, and predict outcomes before treatment begins.</p>
                <a href="#solution" class="btn btn-primary btn-large">Discover The Platform</a>
            </div>
            <div class="hero-image">
                <img src="./k2.svg" alt="Illustration of a molecular network">
            </div>
        </section>

        <section id="problem" class="features">
            <h2>The Problem: Critical Gaps in NSCLC Care</h2>
            <div class="feature-grid">
                <div class="feature-item">
                    <i class="material-icons feature-icon">groups</i>
                    <h3>Target Users & Scope</h3>
                    <p>For oncologists, researchers, and developers in the fight against NSCLC, a disease fueled by complex genetic mutations and molecular networks.</p>
                </div>
                <div class="feature-item">
                    <i class="material-icons feature-icon">error_outline</i>
                    <h3>Critical Pain Points</h3>
                    <p>Care is hindered by blind spots in druggable mutations, tumor resistance to inhibitors like osimertinib, and toxicity from off-target effects.</p>
                </div>
                <div class="feature-item">
                    <i class="material-icons feature-icon">warning</i>
                    <h3>Importance & Urgency</h3>
                    <p>NSCLC claims 1.8M lives annually. Patients demand personalized therapies tailored to their unique tumor networks, as every delay costs lives.</p>
                </div>
                <div class="feature-item">
                    <i class="material-icons feature-icon">science</i>
                    <h3>Current Limitations</h3>
                    <p>Today’s tools analyze single genes, missing the dynamic interplay of mutations and tumor biology that truly drives patient outcomes.</p>
                </div>
            </div>
        </section>

        <section id="solution" class="plans">
            <h2>What You'll Build: The K2 Think Platform</h2>
            <div class="plan-cards">
                <div class="plan-card">
                    <h3>Core Offering</h3>
                    <ul style="margin-top: 30px;">
                        <li>Uncovers pathway disruptions</li>
                        <li>Tests inhibitors virtually for response & resistance</li>
                        <li>Accelerates discovery of new drug targets</li>
                        <li>Enables personalized medicine via patient gene maps</li>
                        <li>Generates onco-specific safety alerts</li>
                    </ul>
                    <a href="#" class="btn btn-outline" style="margin-top: 20px;">Learn More</a>
                </div>
                <div class="plan-card recommended">
                    <span class="badge-recommended">Simple & Powerful</span>
                    <h3>User Flow</h3>
                    <ul style="margin-top: 30px;">
                        <li><strong>Input:</strong> NGS genomic profile and current/planned medications.</li>
                        <li><strong>Process:</strong> K2 Think models the tumor's unique network using NSCLC and drug databases.</li>
                        <li><strong>Output:</strong> Interactive diagram with actionable insights and safety warnings.</li>
                    </ul>
                    <a href="#" class="btn btn-outline" style="margin-top: 20px;">See The Flow</a>
                </div>
                <div class="plan-card">
                    <h3>Tech Stack</h3>
                    <ul style="margin-top: 30px;">
                        <li>K2 Think API for network reasoning</li>
                        <li>Cytoscape.js for visualization</li>
                        <li>Flask backend for data security</li>
                        <li>COSMIC, TCGA, DrugBank, ChEMBL</li>
                        <li>Modular design for easy expansion</li>
                    </ul>
                    <a href="#" class="btn btn-outline" style="margin-top: 20px;">Learn More</a>
                </div>
            </div>
        </section>

        <section id="why" class="features">
            <h2>Why K2 Think</h2>
            <div class="single-column-text">
                <p>K2 Think excels with unparalleled complex systems reasoning and deep data integration, parsing dynamic interactions—genetic mutations, inhibitor mechanisms, tumor microenvironments—to infer causal network relationships. This is critical
                    for decoding NSCLC’s tangled, evolving networks, ensuring predictions guide precise interventions rather than relying on guesswork, a necessity in high-stakes oncology.</p>
            </div>
        </section>

        <section id="demo" class="plans">
            <h2>Demo (MVP)</h2>
            <div class="single-column-text">
                <p>In 48 hours, a live prototype can reconstruct a patient’s specific NSCLC network—not textbook pathways, but their tumor. We can assess the effectiveness of drugs pre-prescription, forecast resistance routes, optimize the regimen, manage
                    drug interactions and toxicity, and explain every recommendation with transparent, literature-backed reasoning.</p>
            </div>
        </section>

    </main>

    <footer>
        <div class="footer-content">
            <div class="footer-links">
                <a href="#">K2 Vynce</a>
                <a href="#">Privacy</a>
                <a href="#">Terms</a>
                <a href="#">About Us</a>
            </div>
            <div class="language-selector">
                <i class="material-icons">language</i>
                <select name="language" id="language">
                    <option value="en-US">English (United States)</option>
                </select>
            </div>
        </div>
    </footer>

    <script src="script.js"></script>
</body>

</html>